Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancerDan Laheru, Gary Croghan, Ronald Bukowski, et al.
Current Problems in Cancer|June 15, 2010
ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentationJoseph Herman, Wells Messersmith, W Warren Suh, et al.
Journal of Pancreatic Cancer|March 29, 2020
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid TumorsMark H O'Hara, Wells Messersmith, Hedy Kindler, et al.
Journal of the American College of Surgeons|December 8, 2016
Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients Undergoing Hepatic Resection for Hepatocellular CarcinomaBrandon C Chapman, Alessandro Paniccia, Patrick W Hosokawa, et al.
Surgery|June 30, 2023
Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancerChristina M Stuart, Michael J Kirsch, Yaxu Zhuang, et al.
Haematologica|April 10, 2025
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 studyTae Min Kim, Nehal J Lakhani, Jacob Soumerai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic CancerEfrat Dotan, Dana B Cardin, Heinz-Josef Lenz, et al.
JCO Oncology Practice|September 30, 2020
Benchmarks for Academic Oncology FacultyLowell Anthony, George Atweh, Ravi Bhatia, et al.
The Oncologist|January 21, 2016
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerLawrence Leichman, Susan Groshen, Bert H O'Neil, et al.
Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.
Pageof 5